SCHEMBL884667

SCHEMBL884667

CCCc1nc(C(Cc2cccnc2N2CCCCC2)c2cccnc2)no1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.38
KCNA5 P22460 9/20 0.37
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 2/20 0.36
TSHR P16473 2/20 0.36
MAPK1 P28482 2/20 0.36
PPARA Q07869 1/20 0.36
KCNH2 Q12809 3/20 0.34
S1PR1 P21453 1/20 0.34
S1PR3 Q99500 1/20 0.34
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
ADRB3 P13945 1/20 0.33
MAPT P10636 2/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
USP2 O75604 1/20 0.33
LMNA P02545 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL886286 0.93 KCNA5 (0.38) HRH3KCNA5MEN1ALDH1A1KMT2A
SCHEMBL885899 0.88 NPC1 (0.37) HRH3KCNA5MEN1ALDH1A1KMT2A
SCHEMBL2063834 0.88 KCNA5 (0.38) HRH3KCNA5MEN1ALDH1A1KMT2A
SCHEMBL884952 0.88 KCNA5 (0.40) KCNA5ALDH1A1TSHRMAPK1KCNH2
SCHEMBL884566 0.87 ALDH1A1 (0.38) HRH3KCNA5MEN1ALDH1A1KMT2A
SCHEMBL2062908 0.87 KCNA5 (0.38) KCNA5ALDH1A1TSHRMAPK1KCNH2
SCHEMBL884959 0.84 KCNA5 (0.37) KCNA5ALDH1A1TSHRMAPK1KCNH2
SCHEMBL885978 0.83 KCNA5 (0.42) HRH3KCNA5ALDH1A1TSHRMAPK1
SCHEMBL885665 0.83 KCNA5 (0.42) HRH3KCNA5ALDH1A1TSHRMAPK1
SCHEMBL884813 0.83 KCNA5 (0.43) KCNA5MEN1ALDH1A1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 HRH3 3415/4885KCNA5 11/4885MEN1 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.